AIM ImmunoTech

|date=AIM ImmunoTech, formerly known as Hemispherx Biopharma, is a small American pharmaceutical company that produces the drug Ampligen. Corporate headquarters are in Orlando, Florida (formerly in Philadelphia, PA) and the main manufacturing and research facility is in New Brunswick, NJ. A second manufacturing plant is in use in Spokane, Washington. |date= |date=In addition to Ampligen® (rintatolimid), AIM ImmunoTech produces Alferon N Injection® and Alferon® LDO (Low Dose Oral). To date, only Alferon N Injection® has FDA approval. Ampligen® and Alferon® LDO are not FDA-approved and are considered experimental. |date= |date=In Jan 2018, Thomas Equels, chief executive officer of AIM ImmunoTech, released a letter instructing every Hemispherx employee to watch the documentary Unrest and urged their affiliates and stockholders to do the same, in an effort to share information about ME/CFS, one of the primary disease targets for their drug Ampligen. |date= |date===Change in leadership== |date= |date=In Feb 2016, Dr. William Carter, then Chairman and CEO, was terminated by the board of directors of Hermispherx Biopharma, now AIM ImmunoTech, who cited that part of the reason was a strong financial austerity plan. William M. Mitchell, M.D., Ph.D. was promoted in house as his replacement. |date= |date=In June 2016, the law suit was resolved between Dr. Carter and Hemispherx, now AIM ImmunoTech, regarding the wrongful termination claim. As part of the settlement, the intellectual property rights, including the patent for Ampligen and Alferon, are irrevocably assigned to to AIM ImmunoTech. |date= |date===Management== |date=*Thomas K. Equels, M.S., J.D. - Executive Vice Chairman, Chief Executive Officer, President, Secretary & General Counsel |date=*Adam Pascale, CPA - Chief Financial Officer |date=* David R. Strayer, M.D. - Chief Scientific & Medical Officer |date=*Wayne Springate - Senior Vice President of Operations |date= |date===Board of directors== |date=* William M. Mitchell, M.D., Ph.D. - Chairman of the Board |date=*Thomas K. Equels, M.S., J.D. - Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel |date=*Peter W. Rodino III, Esq.- Lead Director |date= |date===Marketing history== |date='' |date= |date===Online presence== |date=*Website |date=*SEC filings - Hemispherx Biompharma |date= |date===Talks and interviews== |date=*2016, Small Cap Nation - ME/CFS (Updated) (Thomas Equels) |date= |date===See also== |date=*Ampligen |date=*David Strayer |date=*Marketing History of Ampligen |date=*Thomas Equels |date=*William Carter |date=*William Mitchell |date===Learn more== |date=*Wikipedia - Hemispherx Biopharma |date=*Wikipedia - Rintatolimod |date=*http://simmaronresearch.com/2016/05/hemispherx-ampligen-approval-chronic-fatigue-syndrome-top-priority/ |date=*2014, Investor's post about HEB's rocky history |date=*2016, Hemispherx BioPharma CEO Explains Chronic Fatigue Syndrome And How The Company Is Treating It |date=*2016, Executive Informational Overview by Crystal Research Associates |date=*2016, Hemispherx Biopharma (HEB) Comments on Recent Meeting with NIH for ME/CFS Research Advancement (see also NIH Post-Infectious ME/CFS Study) |date=*2016, Ampligen Co-Inventor / Head of Hemispherx Biopharma Fired: Implications for ME/CFS Drug Unclear |date= |date===References== |date=  |date= |date=